Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ANPEP | P15144 | 2/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.50 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.50 |
| ▸ | LAP3 | P28838 | 2/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17078164 | 1.00 | CA2 (0.59) | CA2ALPIPKMPTGS1XIAP | |
| SCHEMBL4831966 | 0.92 | CA2 (0.52) | CA2 | |
| SCHEMBL8387494 | 0.90 | CA2 (0.61) | CA2ALPIPKMPTGS1XIAP | |
| SCHEMBL21010316 | 0.86 | SLC15A1 (0.64) | CA2ALPIPKMPTGS1XIAP | |
| SCHEMBL27934994 | 0.85 | LAP3 (0.70) | CA2HPGDANPEPRNPEPDNPEP | |
| SCHEMBL7398925 | 0.84 | SLC15A1 (0.51) | CA2ALPIPKMPTGS1XIAP | |
| SCHEMBL28969891 | 0.84 | CA2 (0.55) | CA2ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL4390244 | 0.83 | LAP3 (0.68) | CA2HPGDANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL21457997 | 0.83 | LAP3 (0.68) | CA2HPGDANPEPRNPEPDNPEP | |
| SCHEMBL13340021 | 0.83 | CA2 (0.64) | CA2ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | CA2 1929/4885ALPI 574/4885PKM 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.